Georgia medtech startup Cartiva just closed out an $8.5 million Series D, which will fund the company through PMA approval for its synthetic cartilage implant meant for those with osteoarthritis. It submitted a PMA application to the FDA just last month. The dollars will also fund Cartiva’s post-510(k) clinical trials on its ProxiFuse Hammertoe Correction System … Continue reading Cartiva closes out $8M Series D to bring its synthetic cartilage product geared at osteoarthritis to U.S. market